|
 
- 积分
- 414
- 威望
- 414
- 包包
- 645
|
本帖最后由 细胞海洋 于 2014-1-4 09:43 编辑
4 B) s+ q* R! s: r) H
5 z O1 A2 `* F# `1 _# sMolecular therapies
' n) [; W# J% d' B2 g/ r! JDr. Zoltán Balajthy, Dr. János Aradi, Dr. Zoltán Balajthy, Dr. Éva Csősz, Dr. Beáta Scholtz, Dr. István Szatmári, Dr. József Tőzsér, Dr. Tamás Varga (2011)
* a2 a! @1 v: E
+ \# j: N5 L0 b( Z- dUniversity of Debrecen i% S X: S; r* H9 W6 K+ m
Copyright © 2011 The project is funded by the European Union and co-financed by the European Social Fund., Manuscript completed: 17 November 2011
g. P) X7 b7 Y
Y$ u: H' q0 U/ g5 G
& o7 [* \ r7 q% g( e( L
% ~& [4 {; d2 X% c6 uIndex) a+ k a- a: O3 D
1. 1. Functional Genomics8 {8 t) }$ I$ P# y
1.1 Definitions2 S4 g$ ~1 w/ R ~: o6 H5 o5 z
1.2 About diseases5 g: x; P& h! w, A/ d
1.3 Approaches to understanding disease mechanisms4 o# l S% y9 Y# j# [ C
1.3.1 Gene expression is regulated in several basic ways9 Q" S" t; h. J2 w! T
1.3.2 Microarrays: functional genomics in cancer research
. X" D( T, C( m; |1.3.3 A Variety of Genetic Alterations Underlie Developmental Abnormalities and Disease% I1 @9 Q# Y5 P F- S( P
1.3.4 Genomic microarrays: x! c V* `! i
2. 2. Recombinant proteins, Z: s/ ^" o c4 ]' ]
2.1 Overview: Protein pharmaceuticals' h! _2 g8 [ y
2.2 Cell-free systems: In vitro transcription and translation6 J" c* d% k3 X7 t! _+ P- r$ |1 Z# a/ z
2.3 Recombinant protein expression in isolated cells (cell culture)
" a9 Y9 D! E9 ~' x$ k2.4 Non-prokaryotic expression systems
$ ?% P" w( G6 }/ e! ]2.4.1 Cloning in Pichia pastoris
* _" x, \- w$ [/ r& ^2 f2.4.2 Baculovirus mediated protein expression in insect cells$ Y; |& U8 F# m' k! L4 k, e! M
2.4.3 Mammalian expression systems2 t7 S8 s" H. g' W) z
2.5 Purification of recombinant proteins* @" T) i- U. Y, P$ I
3. 3. Gene Therapy: Vectors and Strategies.
+ k% b/ a6 m# H7 H3 {# U3.1 Vectors for Gene Therapy/ p. l, ^" k" ^8 f
3.2. Types of gene transfer, vectors for gene therapy" o e' o8 G$ A4 S6 W
3.3. General gene therapy strategies9 o& F3 P( f) K7 Z
3.4. Human gene therapy" Y. w; u- R5 I" G2 U7 \7 q
4. 4. Protein replacement therapies.3 f# n: o9 G4 a: g0 a0 `" j
5. 5. Recombinant antibodies and the phage display technology, f4 w+ ]) B! R& e3 l6 d* ~
5.1. Introduction
1 o$ {% Y ^2 ~# d" M: j; P& _5.1.1. The structure of antibodies and their production in the body4 q$ m$ d' G$ t: i; m
5.1.2. Antigen-antibody binding
5 ~6 h! K" X" Y3 Q& v5.2. The production of therapeutic antibodies
7 x, Y8 L1 L/ T8 x5.2.1. The production of antibodies in hybridoma cells.1 s* K, a* {$ `! P# N
5.2.2. Humanized antibodies( m! ?% Q9 ~% t% Y+ h' s+ T. M
5.2.3. Production of human antibodies. [- j. ?& R& e4 d A
5.3. Generation of antibodies by phage display
8 s; @3 P9 L, \( T0 J" C5 z5.3.1. The phage display technology1 j& L4 F7 U/ e0 @
5.3.2. Generation of phage libraries) z2 s$ @' q- a
5.4. Administration of therapeutic antibodies
9 a* t; B* ?3 H6 l: m7 u6. 6. Anti-cytokine Therapy (sepsis).6 L' T) W6 O8 Z0 e: N0 D- u1 l3 q7 X/ a
6.1. The consequences of developing inflammation2 l! Y h+ c' _( ^& k$ V
6.2. Development of Inflammatory Response: Synthesis of Lipid Mediators% f; a5 L# s$ X6 _. O
6.3. Role of the Liver in Maintenance of Homeostasis: Acute Phase Response
* \# y0 T* u. J6 h1 h6.4. Time-Course of the Inflammatory Response During Sepsis! d* g: q1 q3 r$ N
7. 7. Animal models and transgenesis in biotechnology
, R0 b& p7 n: N, p. w6 V8. 8. Embryonic and adult stem cells in regenerative medicine I.& I, U; \" J& T" Y# z4 U
8.1 Embryonic stem cells
! ^" I7 P* ~1 T6 u) i' c' H8.2 Somatic cell reprogramming into pluripotent stem cells- _% M, D) A0 d7 m
8.3 Adult stem cells; D- u; J0 r2 _# ^
9. 9. Embryonic and adult stem cells in regenerative medicine II.
/ t1 d# R3 Z5 `2 R$ G9 S9.1 Pluripotent stem cells for regenerative medicine: b$ Z8 k8 a) x G# `: B/ A
9.2 Clinical application of stem cells; e: G# E1 ~2 m2 t! B2 B8 ` U4 W
9.3 Stem cell therapy to cure various diseases; j0 b4 B0 f2 |; {+ a8 d
10. 10. Cell Cycle and Cancer Therapy, p53 I.
* k5 X- `8 e2 u7 W) J10.1 Cell Cycle
" A& q& @ t. _( f3 ~7 _! b9 ]10.2. Mitogenic Signaling in Eukaryotic Cell Controls the Rate of Cell Division# B8 p- J' h% [- B {, s9 z$ F( W
10.3. Biochemical Events of Cell-cycle – in M Phase( b e* i: b) N, ~7 h- w3 S$ i
10.4. Protooncogenes) Z, O& A# ^' |" y' c' ?# [
10.5. ErbB/HER Receptors$ [# O9 Q4 k; k7 ]: `" ~9 X
10.6. Therapeutic targets
; k5 D+ {/ c4 g11. 11. Cell Cycle and Cancer Therapy, p53 II.
( @* l, e1 r) A( d6 a% O11.1. Tumor Suppressor Genes and p53
3 M8 P% R w- l6 y3 r! q11.2. Biochemical Pathways of Apoptosis and its Therapeutic Utilization8 u6 A0 n0 m7 n
12. 12. Gene Silencing Technologies.+ ~% N+ R2 Z; H
12.1 Introduction7 h7 O; N! O) q( u K/ k4 R
12.2 Action of antisense oligonucleotides+ m( a3 N) [6 F- S( \
12.3 Chemical modifications of gene silencing oligonucleotides; general considerations
# s8 l+ H/ {5 @# K12.4 Inhibition of transcription by triple helix forming oligonucleotides+ E" U7 |! S/ N4 R! r4 w
12.5 Gene silencing by ribozymes9 c9 c% {. @' I" Z3 u
12.6 Gene silencing with short RNA fragments
5 Q& L. d+ C& w5 p. {5 i. w12.7 Important final note, y6 d6 ^2 V6 ^0 q+ V: C l
' M f" }$ d/ M5 F[hide][/hide] |
附件: 你需要登录才可以下载或查看附件。没有帐号？注册
-
总评分: 威望 + 5
包包 + 20
查看全部评分
|
发表于 2014-1-3 16:18
